α adrenergic receptor Ligand

(+)-Niguldipine hydrochloride is a 1,4-DHP receptor ligand associated with L-type Ca²⁺ channels (with K_i values of 85 pmol/L in guinea pig skeletal muscle, 140 pmol/L in brain, and 45 pmol/L in heart) as well as an α₁-adrenergic receptor ligand (with a K_i value of 78 nmol/L). (+)-Niguldipine hydrochloride shows much higher binding selectivity for α_1α-adrenergic receptors than for α_1B-adrenergic receptors. (+)-Niguldipine hydrochloride can be used in studies related to hypertension.

Iloperidone carboxylic acid (P95-12113) is the metabolite of Iloperidone (HY-17410). Iloperidone carboxylic acid exhibits good affinity for 5-HT2A receptor with pK_i of 8.15, and moderate affinity for adrenergic receptor α1/α2B/α2C.

(+)-Niguldipine is a 1,4-DHP receptor ligand associated with L-type Ca²⁺ channels (with K_i values of 85 pmol/L in guinea pig skeletal muscle, 140 pmol/L in brain, and 45 pmol/L in heart) as well as an α₁-adrenergic receptor ligand (with a K_i value of 78 nmol/L). (+)-Niguldipine shows much higher binding selectivity for α_1α-adrenergic receptors than for α_1B-adrenergic receptors. (+)-Niguldipine can be used in studies related to hypertension.

Z8779877149 (Z7149) is a blood-brain barrier-permeable multi-target ligand that targets SERT (K_i=198 nM), α2A adrenergic receptor (K_i=180 nM; EC₅₀=440 nM) and 5-HT_2A receptor (EC₅₀=172 nM, E_max=76%). Z8779877149 inhibits 5-HT reuptake and activates G_i and Gq protein signaling pathways, respectively. Z8779877149 effectively alleviates pain responses as well as depression- and anxiety-like behaviors, while exhibiting favorable safety without inducing sedation or motor impairment. Z8779877149 is available for the research of pain, depression and anxiety disorders.

α1A-AR ligand-1 (Compound 3) is an α1A-AR ligand that can be used to synthesize PROTACs, such as α1A-AR Degrader 9c (HY-147100).

Platelet aggregation-IN-3 (Compound 5) is a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis.